卡巴拉汀联合司来吉兰治疗帕金森病的临床研究  

Clinical study on rivastigmine combined with selegiline in treatment of Parkinson disease

作　　者：李晨曦[1] 张一帆[2] 白如玉[1] 郝美美[1] LI Chen-xi;ZHANG Yi-fan;BAI Ru-yu;HE Mei-mei(Department of Neurology, Yan'an People’s Hospital, Yan'an 716000, China;Yanan People’s University Affiliated Hospital, Yan'an 716000, China)

机构地区：[1]延安市人民医院神经内科,陕西延安716000 [2]延安大学附属医院,陕西延安716000

出　　处：《现代药物与临床》2019年第8期2356-2360,共5页Drugs & Clinic

摘　　要：目的研究卡巴拉汀联合司来吉兰治疗帕金森病临床效果。方法选取2016年3月-2017年6月在延安市人民医院治疗的帕金森患者100例,随机分为对照组和治疗组,每组各50例。对照组口服盐酸司来吉兰片,5mg/次,2次/d;治疗组在对照组基础上口服重酒石酸卡巴拉汀胶囊,3mg/次,2次/d。两组患者均治疗12周。观察两组患者临床疗效,同时比较治疗前后两组患者Mo CA、简易精神状态量表(MMSE)、统一帕金森病评分量表(UPDRS)和自主神经症状量表(SCOPT-AUT)评分,血清胰岛素样生长因子(IGF-1)、β-淀粉样蛋白1-42(Aβ1-42)水平和多巴胺转运体(DAT)活性。结果治疗后,对照组和治疗组临床有效率分别为64.00%和86.00%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者UPDRS和SCOPT-AUT评分显著降低(P<0.05),Mo CA和MMSE评分显著升高(P<0.05),且治疗组这些评分明显好于对照组(P<0.05)。治疗后,两组血清Aβ1-42和IGF-1水平显著升高(P<0.05),且治疗组Aβ1-42和IGF-1水平明显高于对照组(P<0.05)。治疗后,两组患侧和健侧评分显著降低(P<0.05),且治疗组DTA活性明显低于对照组(P<0.05)。结论卡巴拉汀联合司来吉兰治疗帕金森患者能够有效缓解患者症状,升高血清Aβ1-42和IGF-1水平,延缓DAT失活速度。Objective To investigate the clinical effect of rivastigmine combined with selegiline in treatment of Parkinson disease.Methods Patients(100 cases) with Parkinson disease in Yan’an People’s Hospital from March 2016 to June 2017 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Selegiline Hydrochloride Tablets, 5 mg/time, twice daily. Patients in the treatment group were po administered with Rivastigmine Hydrogen Tartrate Capsules on the basis of the control group, 3 mg/time, twice daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and MoCA, MMSE, UPDRS and SCOPT-AUT scores, serum IGF-1 and Aβ1-42 levels,and DAT activity in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 64.00% and 86.00%, respectively, and there were differences between two groups(P < 0.05). After treatment, the UPDRS and SCOPT-AUT scores in two groups were significantly decreased(P < 0.05), but MoCA and MMSE scores were significantly increased(P < 0.05), and these scores in the treatment group were significantly better than those in the control group(P < 0.05). After treatment, the serum IGF-1 and Aβ1-42 levels in two groups were significantly increased(P < 0.05), and which in the treatment group were significantly higher than those in the control group(P < 0.05). After treatment, the ST/OC of both sides scores in two groups were significantly decreased(P < 0.05), and the DAT activity in the treatment group were significantly lower than those in the control group(P < 0.05). Conclusion Rivastigmine combined with selegiline can effectively relieve symptoms in treatment of Parkinson disease, increase serum Aβ1-42 and IGF-1 level and delay the DAT inactivation rate.

关 键 词：重酒石酸卡巴拉汀胶囊 盐酸司来吉兰片 帕金森病 淀粉样蛋白1-42 血清胰岛素样生长因子-1 多巴胺转运体 

分 类 号：R971[医药卫生—药品]